Invest in Vegalab
Scalable biotech platform in agrobiologicals, biosecurity, water and cosmetics — proprietary nano-encapsulation technology, 40–80% gross margins and a capital-efficient international expansion model.
Company snapshot
Vegalab SA is a Swiss biotech enterprise headquartered in Zug, Switzerland. We develop and manufacture natural product solutions utilising proprietary formulation technologies — including micronization and nano-encapsulation — that enhance stability, penetration and performance while maintaining cost competitiveness against conventional synthetic alternatives.
Our operations span four business verticals — Crop Science, Beauty Science, Life Sciences and Biosecurity — all built on a single shared technology platform. This gives us diversified revenue streams with shared R&D economics and a clear path to cross-vertical leverage as the platform matures.
We are FDA registered as a cosmetic product manufacturer and EPA registered as a natural agrochemical product manufacturer. All worldwide operations are 100% carbon neutral.
Investment highlights
Six structural advantages that make Vegalab a differentiated opportunity in the natural products biotech sector.
Proprietary technology platform
Multi-layer nano-encapsulation with up to 20 programmable trigger-responsive layers — protecting sensitive actives, improving solubility and controlling release. A genuine moat, not a formulation tweak.
Multi-vertical revenue diversification
Four distinct end-markets (crop, beauty, life sciences, biosecurity) share one R&D infrastructure, reducing risk concentration and creating natural cross-selling and licensing opportunities.
Capital-efficient expansion model
Growth scales through distribution partners and country-level joint ventures with exclusive territory rights. Capital is directed toward inventory, registrations and sales execution — not fixed infrastructure.
Regulatory credentialing
FDA and EPA registration, OMRI listing and FSC certification represent meaningful regulatory work already done — a barrier to competition that takes years and significant capital to replicate.
Third-party validation
Proof points from commercial distributors, major university trial programmes, independent labs and 200+ industry report references position Vegalab as a credible, established participant — not early-stage.
Structural tailwinds
Global regulatory pressure on synthetic pesticides, consumer demand for clean-label food and cosmetics, and ESG capital flows all favour high-performance natural products. Vegalab is positioned at the centre of this shift.
What investors gain access to
Direct investment or country-level franchise/JV structures with exclusive territory rights and clear paths to liquidity.
US, Canada & international market expansion
Scalable expansion into the US, Canada and high-potential international markets via direct investment into operations and country-level franchise/JV structures — each with exclusive territory rights and a clear path to liquidity.
Documented revenue history
Historical revenues with public audit documentation from prior operations. Gross margin ranges of ~40–80% depending on product and channel mix, validated across both B2B agrochemical and B2C consumer channels.
Franchise and territory models
Country operating companies can be structured as exclusive territory franchises, giving investors both the upside of local market development and the IP leverage of the Vegalab platform without duplicating core R&D spend.
Technology licensing potential
The nano-encapsulation platform has licensing potential beyond current verticals — agrochemical majors, cosmetic contract manufacturers and pharmaceutical delivery applications represent additional monetisation pathways.
Key milestones
Vegalab's trajectory from Swiss startup to multi-vertical, multi-continent biotech operation.
Vegalab SA incorporated in Zug, Switzerland
Nano-encapsulation platform developed; first crop science product line formulated.
EPA registration & first US distribution
Products registered with the EPA; initial distribution agreements signed with US agricultural wholesalers.
OMRI listing & Beauty Science launch
Key crop inputs achieved OMRI listing for organic production. NanoSerum skincare line launched under Beauty Science division.
National Hemp Expo award & Asia-Pacific entry
Named Best Fertilizer Company at the National Hemp Expo. Distribution partnerships established in Singapore, South Korea and Hong Kong.
Biosecurity division & FSC certification
PureTabs biosecurity product range launched. FSC certification awarded. University trial programme expanded to five institutions.
Active investment round — US & Canada expansion
Seeking capital partners for US/Canada market acceleration and country-level JV structures. Investor materials available under NDA.
Request investor materials
We share detailed financials, technology documentation, trial data and investment structure terms selectively with qualified investors under NDA. If you are a fund, family office, strategic partner or accredited individual investor, we welcome your enquiry.
Request investor materials